A clinical trial of SOL686 in patients with Glioma.
Latest Information Update: 25 Mar 2021
At a glance
- Drugs SOL 686 (Primary)
- Indications Glioma
- Focus Adverse reactions
Most Recent Events
- 23 Mar 2021 According to a Phoremost media release, the company plans to initiate this study in 2022.
- 10 Nov 2019 New trial record
- 04 Nov 2019 According to a Phoremost media release, the company plans to initiate this study in 2021.